Arvinas (NASDAQ:ARVN) Announces Earnings Results

Arvinas (NASDAQ:ARVN) issued its quarterly earnings results on Tuesday. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44, Zacks reports.

Arvinas Stock Performance

ARVN opened at $18.97 on Tuesday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The company’s 50-day moving average is $19.46 and its 200 day moving average is $23.44.

Analysts Set New Price Targets

ARVN has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research report on Friday. BTIG Research began coverage on shares of Arvinas in a research report on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. Oppenheimer cut their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. BMO Capital Markets cut their price objective on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. Finally, HC Wainwright reissued a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, Arvinas has a consensus rating of “Moderate Buy” and a consensus target price of $61.45.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.